@article{b3dc50b0a5fb4314ba6e6a2f79579445,
title = "Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study",
keywords = "blood, cll, european-society, follow-up, retrospective analysis, CLL, FOLLOW-UP, RETROSPECTIVE ANALYSIS, EUROPEAN-SOCIETY, BLOOD",
author = "J. Schetelig and J. Hoek and S. Stilgenbauer and J.M. Middeke and N.S. Andersen and C.P. Fox and S. Lenhoff and L. Volin and A. Shimoni and W. Schroyens and {van Gelder}, M. and D. Bunjes and {van Biezen}, A. and H. Baldauf and {de Wreede}, L.C. and O. Tournilhac and N. Kroger and I. Yakoub-Agha and P. Dreger",
note = "Funding Information: Conflict of interest JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.",
year = "2021",
month = mar,
day = "1",
doi = "10.1038/s41409-020-01013-y",
language = "English",
volume = "56",
pages = "692--695",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "3",
}